Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Belsomra Again Grabs Number 1 Spot in December Anterio Ranking
February 4, 2015
- AbbVie Publishes Japanese PIII Study Results for Hepatitis C Treatment
February 4, 2015
- Astellas to Disclose Detailed Clinical Study Data on Approved Drugs
February 4, 2015
- Wave of Downsizing (2): Job Cuts at Non-Japanese Makers Also Come to Fore
February 4, 2015
- Astellas, Osaka University Join Hands in Cell Therapy Research
February 3, 2015
- Sumitomo Dainippon Revving Up “Post-Latuda” Development Drive
February 3, 2015
- 2014 Was “Difficult Year” as Generics Gained Ground: Kyowa Kirin Pres.
February 3, 2015
- Takeda Terminates Development of Combined Quadruple Vaccine
February 3, 2015
- Wave of Downsizing (1): Major Japan Drug Makers Offer Voluntary Redundancies
February 3, 2015
- Drug Price Cuts, Generic Erosion Weigh Kyowa Kirin Earnings
February 2, 2015
- Over 500 Daiichi Sankyo Employees Take Voluntary Redundancy
February 2, 2015
- Astellas Licenses Pollinosis Vaccine from Immunomic Therapeutics
February 2, 2015
- Kyowa Hakko Bio Names Mr Kotani as New President
February 2, 2015
- Chugai to Set Up Global Organization to Bolster Early Clinical Development Functions
January 30, 2015
- Abilify Rakes in US Sales of Nearly US$5 Billion in 2014: Otsuka
January 29, 2015
- Chugai Sales Grow 8.8% Thanks to Increasing Actemra Exports
January 29, 2015
- Astellas, Takeda to Lead Pack in FY2018 Japan Pharma Market: Citi Analyst
January 29, 2015
- Otsuka Establishes Marketing Base in Australia
January 29, 2015
- Astellas to Transfer Marketing Rights for 3 APIs to OrphanPacific
January 28, 2015
- PD-1, PD-L1 Inhibitors Could Carve Out 750 Billion Yen Market in Japan: Citi Analyst
January 28, 2015
ページ
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s FY2026 drug pricing reform is set to usher in a new phase for the generics market, effectively bringing an…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…